Savara Inc
$ 5.79
5.08%
06 Aug - close price
- Market Cap 1,129,149,000 USD
- Current Price $ 5.79
- High / Low $ 5.81 / 5.52
- Stock P/E N/A
- Book Value 0.69
- EPS -0.57
- Next Earning Report 2026-08-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.40 %
- ROE -0.80 %
- 52 Week High 7.00
- 52 Week Low 2.43
About
Savara Inc. is a lung disease orphan company. The company is headquartered in Austin, Texas.
Analyst Target Price
$10.94
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-13 | 2025-11-12 | 2025-08-13 | 2025-05-13 | 2025-03-27 | 2024-11-12 | 2024-08-12 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-10 |
| Reported EPS | 0 | -0.13 | -0.14 | -0.14 | -0.12 | -0.13 | -0.11 | -0.12 | -0.11 | -0.09 | -0.1 | -0.07 |
| Estimated EPS | -0.1183 | -0.12 | -0.13 | -0.12 | -0.128 | -0.11 | -0.11 | -0.11 | -0.1 | -0.1 | -0.07 | -0.08 |
| Surprise | 0.1183 | -0.01 | -0.01 | -0.02 | 0.008 | -0.02 | 0 | -0.01 | -0.01 | 0.01 | -0.03 | 0.01 |
| Surprise Percentage | 100% | -8.3333% | -7.6923% | -16.6667% | 6.25% | -18.1818% | 0% | -9.0909% | -10% | 10% | -42.8571% | 12.5% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-12 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.14 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SVRA
2026-08-05 17:15:27
Savara Inc. is set to report second-quarter earnings, with analysts expecting a loss of $0.145 per share. The clinical-stage biotech company is preparing for a crucial FDA decision on its lead drug candidate, molgramostim, for which it has a PDUFA date set for November 22, 2026. Investors are closely watching the company's cash position, burn rate, and progress on commercial infrastructure ahead of the potential approval.
2026-08-05 10:15:27
This article revisits Savara Inc. (SVRA), focusing on its APAP BLA filing progress and identifying the upcoming APAP BLA PDUFA as a pivotal near-term catalyst. The author, who previously rated Savara as a "Buy," highlights the company's clinical and regulatory milestones as key investment drivers. The investment thesis centers on SVRA's execution and regulatory pathway for APAP, with a focus on monitoring the launch of MOLBREEVI if approved.
2026-08-04 20:10:38
Savara Inc., a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, announced its participation in the 2026 Jefferies Global Healthcare Conference. Members of their management team will host one-on-one meetings and a fireside chat on June 3rd, 2026. A live webcast and replay of the event will be available on the company's corporate website.
2026-07-31 05:40:15
Levi & Korsinsky is urging shareholders of Savara Inc. (SVRA) who suffered losses between March 4, 2024, and May 23, 2025, to act before the lead plaintiff deadline of November 7, 2025. A class action lawsuit alleges that Savara Inc. made false and misleading statements regarding the regulatory approval of its drug MOLBREEVI and potential capital needs. Shareholders can visit the firm's website or contact Joseph E. Levi to learn more about their rights to seek recovery.
2026-07-30 21:11:21
Savara Inc. announced that the European and Australian Patent Offices have granted patents for the liquid formulation of MOLBREEVI, providing intellectual property protection until March 2041 in both regions. These patents strengthen Savara's position in ex-US markets for its investigational drug, which is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (PAP). The company is also pursuing similar patent filings in the U.S., including for the drug-device combination.
2026-07-28 06:10:14
This article provides a comprehensive stock analysis of Savara Inc (SVRA) from TradingKey, highlighting its relatively weak fundamentals but high growth potential and fairly valued status within the Biotechnology & Medical Research industry. Key insights include very high institutional ownership, recent "Buy" ratings from analysts with a target price of $10.94, and an expected upward trend in the medium term despite recent weak market performance. The company specializes in rare respiratory diseases, with its lead program, molgramostim inhalation solution (MOLBREEVI), in Phase III development.
